Fresenius Medical Care AG (FMS) Shares Gap Up to $43.60
Fresenius Medical Care AG (NYSE:FMS) shares gapped up prior to trading on Friday . The stock had previously closed at $42.98, but opened at $43.60. Fresenius Medical Care AG shares last traded at $44.66, with a volume of 75,439 shares.
FMS has been the topic of several recent research reports. Jefferies Group upgraded shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research report on Friday, July 8th. DZ Bank AG reiterated a “neutral” rating on shares of Fresenius Medical Care AG in a research report on Thursday, August 4th. Royal Bank Of Canada reiterated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 24th. Berenberg Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, August 9th. Finally, Robert W. Baird reiterated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Monday, May 16th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $42.50.
The company has a market cap of $27.34 billion and a price-to-earnings ratio of 24.78. The company’s 50-day moving average is $45.35 and its 200-day moving average is $43.58.
Fresenius Medical Care AG (NYSE:FMS) last announced its earnings results on Tuesday, August 2nd. The company reported $0.96 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.04. The company had revenue of $4.42 billion for the quarter, compared to analyst estimates of $4.54 billion. On average, equities analysts predict that Fresenius Medical Care AG will post $2.01 earnings per share for the current year.
Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.